Trastuzumab in combination with PEGylated interferon-alpha 1b exerts synergistic antitumor activity through enhanced inhibition of HER2 downstream signaling and antibody-dependent cellular cytotoxicity
文献类型：期刊论文
| 作者 | Xu, Piaopiao1,2; Chen, Xiangling1; Xu, Yongping1; Fu, Li1; Li, Yun1; Fu, Haoyu1; Yao, Qing1; Quan, Haitian1 ; Lou, Liguang1,2
|
| 刊名 | AMERICAN JOURNAL OF CANCER RESEARCH
 |
| 出版日期 | 2022 |
| 卷号 | 12期号:2页码:549-561 |
| 关键词 | Trastuzumab PEGylated IFN-alpha 1b ADCC HER2-positive cancer synergistic effect |
| ISSN号 | 2156-6976 |
| 通讯作者 | Quan, Haitian(haitianquan@163.com) ; Lou, Liguang(lglou@simm.ac.cn) |
| 英文摘要 | The anti-HER2 monoclonal antibody trastuzumab is the mainstay of treatment for HER2-positive breast and gastric cancer, and its combination with multiple chemotherapeutic agents has represented an effective and rational strategy in the clinic. In this study, we report that trastuzumab in combination with PEGylated interferon-alpha 1b (IFN-alpha 1b), a polyethylene glycol (PEG)-conjugated form of a subtype of interferon alpha (IFN-alpha), synergistically inhibited the proliferation of HER2-positive cells, including BT-474 and SK-BR-3 breast cancer cells and NCI-N87 gastric cancer cells, and also induced their apoptosis, but had no effect on HER2-negative MDA-MB-231 breast cancer cells. Trastuzumab inhibited phosphorylation of HER2, AKT and ERK, an effect that was enhanced by PEGylated IFN-alpha 1b, likely owing to PEGylated IFN-alpha 1b-mediated downregulation of HER2 through the lysosomal degradation pathway. Moreover, PEGylated IFN-alpha 1b significantly enhanced trastuzumab-mediated antibody-dependent cellular cytotoxicity (ADCC) in HER2-positive cells. Importantly, trastuzumab combined with PEGylated IFN-alpha 1b exhibited significant synergistic antitumor activity in HER2-positive BT-474 xenografts, an effect that was associated with enhanced inhibition of HER2 expression and AKT and ERK phosphorylation. Strikingly, depletion of natural killer cells with anti-Asialo GM1 antibody abrogated the synergistic antitumor activity, indicating that augmented ADCC is essential for this synergy. Taken together, our findings indicate that both enhanced inhibition of HER2 downstream signaling and augmented ADCC contribute to the synergistic antitumor activity of trastuzumab with PEGylated IFN-alpha 1b, and imply that combining trastuzumab with PEGylated IFN-alpha 1b could be a promising strategy for HER2-positive cancers. |
| WOS关键词 | NECK-CANCER CELLS ; BREAST-CANCER ; IFN-ALPHA ; HEPATOCELLULAR-CARCINOMA ; MAINTENANCE THERAPY ; I INTERFERONS ; EFFICACY ; SYSTEM ; VITRO ; HEAD |
| 资助项目 | Science and Technology Commission of Shanghai Municipality[18DZ2293200] ; Yunnan Province Sciences and Technology plan[2017ZF010] |
| WOS研究方向 | Oncology |
| 语种 | 英语 |
| WOS记录号 | WOS:000765695800007 |
| 出版者 | E-CENTURY PUBLISHING CORP |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/300227]  |
| 专题 | 中国科学院上海药物研究所 |
| 通讯作者 | Quan, Haitian; Lou, Liguang |
| 作者单位 | 1.Chinese Acad Sci, Shanghai Inst Mat Med, 555 Zuchongzhi Rd, Shanghai 201203, Peoples R China 2.Univ Chinese Acad Sci, 19A Yuquan Rd, Beijing 100049, Peoples R China |
| 推荐引用方式 GB/T 7714 | Xu, Piaopiao,Chen, Xiangling,Xu, Yongping,et al. Trastuzumab in combination with PEGylated interferon-alpha 1b exerts synergistic antitumor activity through enhanced inhibition of HER2 downstream signaling and antibody-dependent cellular cytotoxicity[J]. AMERICAN JOURNAL OF CANCER RESEARCH,2022,12(2):549-561. |
| APA | Xu, Piaopiao.,Chen, Xiangling.,Xu, Yongping.,Fu, Li.,Li, Yun.,...&Lou, Liguang.(2022).Trastuzumab in combination with PEGylated interferon-alpha 1b exerts synergistic antitumor activity through enhanced inhibition of HER2 downstream signaling and antibody-dependent cellular cytotoxicity.AMERICAN JOURNAL OF CANCER RESEARCH,12(2),549-561. |
| MLA | Xu, Piaopiao,et al."Trastuzumab in combination with PEGylated interferon-alpha 1b exerts synergistic antitumor activity through enhanced inhibition of HER2 downstream signaling and antibody-dependent cellular cytotoxicity".AMERICAN JOURNAL OF CANCER RESEARCH 12.2(2022):549-561. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。